# **Challenge Virus:** Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

# **Experimental Summary:**

Veridical Efficacy Test for Device with AHPCO Technology against the challenge virus Middle East Respiratory Syndrome Coronavirus (MERS-CoV), BEI Resources, with host Vero E5 cells, ATCC CRL-1586. Contact times 1 hour, 2 hours and 4 hours.

## Study Dates & Procedure:

A glass carrier was inoculated with 0.2 mL of virus in a 4 in2 area and dried for 18 minutes at 20°C. Exposure distance approximately 5 cm. The test device was assembled and operated safely according to the manufacturer or Sponsor's instructions. The laboratory phase of this test was performed at MicroBioTest, 105 Carpenter Drive, Sterling, VA 20164, from 05/26/16 to 06/03/16. Titer Results:

Sample	Replicate	Contact time	Titer (Log <sub>10</sub> TCID <sub>60</sub> /mL)	Volume (mL)	Viral Load (Log <sub>10</sub> TCID <sub>50</sub> )	
Cell viability/media sterility control	NA		no virus detected, cells viable; media sterile			
Virus Stock Titer Control			7.75	-	-	
Theoretical load <sup>a</sup>					7.05	
STR-Solution	1	1 hour	5.25	0.2	4.55	
	2		5.00	0.2	4.30	
	3		4.50	0.2	3.80	
	1	2 hours	4.00	0.2	3.30	
	2		4.00	0.2	3.30	
	3		3.75	0.2	3.05	
	1	4 hours	3.00	0.2	2.30	
	2		2.30	0.2	1.60	
	3		2.75	0.2	2.05	
Initial Plate Recovery Control (T = 0 hours)	1	0 hours	7.00	0.2	6.30	
	2		7.25	0.2	6.55	
	3		7.25	0.2	6.55	
	Average				6.48	
Final Plate Recovery Control (T = 4 hours)	1	4 hours	5.75	0.2	5.05	
	2		6.00	0.2	5.30	
	3		6.50	0.2	5.80	
	Average				5.50	

a The theoretical load is determined based on the Virus Stock Titer control and the volume of virus challenged per carrier. NA = Not applicable

> SUMMARY OF MICROBAC ANALYSIS OF THE AHPCO PROPRIETARY TECHNOLOGY

#### **RESULTS** (continued):

#### Table 2 Cytotoxicity Controls

Dilution of the Neutralized Sample	Cytotoxicity Control		
10 <sup>-2</sup>	no cytotoxicity observed in 4 out of 4 wells		
10 <sup>-3</sup>	no cytotoxicity observed in 4 out of 4 wells		
10 <sup>-4</sup>	no cytotoxicity observed in 4 out of 4 wells		

Viral Reduction										
Test Agent	Contact Time	Replicate Number	Initial Viral Load* (Log <sub>10</sub> TCID <sub>60</sub> )	Output Viral Load (Log <sub>10</sub> TCID <sub>60</sub> )	Log <sub>10</sub> Reduction	Percent Reduction				
STR-Solution	1 hour	1	6.48	4.55	1.93	98.829%				
		2		4.30	2.18	99.342%				
		3		3.80	2.68	99.792%				
		Mean Reduction			2.38	99.582%				
	2 hours	1	6.48	3.30	3.18	99.934%				
		2		3.30	3.18	99.934%				
		3		3.05	3.43	99.963%				
		Mean Reduction			3.28	99.948%				
	4 hours	1	6.48	2.30	4.18	99.993%				
		2		1.60	4.88	99.999%				
		3		2.05	4.43	99.996%				
		Mean Reduction			4.59	99.997%				

#### Table 3 Viral Reduction

\* Results represent the average of three replicates.

## **Conclusions/Observations:**

When tested as described, the AHPCO device exhibited a 2.38, 3.28 and 4.59 Log10 (99.582%, 99.948%, 99.997%) reduction when Middle East Respiratory Syndrome Coronavirus (MERS-CoV), containing 5% serum, was exposed to the test device for 1 hour, 2 hours and 4 hours respectively at 20°C. All of the controls met the criteria for a valid test. These conclusions are based on observed data.

## SUMMARY OF MICROBAC ANALYSIS OF THE AHPCO PROPRIETARY TECHNOLOGY